AGONISTIC AND ANTAGONISTIC INTERACTIONS OF ANTI-INTERLEUKIN 2 RECEPTOR MONOCLONAL ANTIBODIES IN RAT RECIPIENTS OF CARDIAC ALLOGRAFTS
- 1 January 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 47 (1) , 11-16
- https://doi.org/10.1097/00007890-198901000-00004
Abstract
A panel of five mouse mAbs recognizing 4 distinct epitopes (R1-4) of the rat 55kD IL-2R molecule were tested for their influence on acute rejection (8 days) of (LEW .times. BN)F1 cardiac allografts in LEW hosts. IL-2R1 targeted therapy with ART-18 (IgG1, inhibits IL-2-dependent responses) prolonged graft survival to ca. 21 days. IL-2R2 is recognized by ART-65 and ART-75, mAbs that do not inhibit T cell growth. Treatment with ART-65 (IgG1) but not ART-75 (IgG2a) abrogated acute rejection (ca. 16 days and 9 days, respectively). ART-35, an anti-IL-2R3 mAb (IgG1, does not inhibit T cell function) extended graft survival marginally to ca. 12 days. Finally therapy with OX-39, (anti-R4 IgG1 mAb, inhibits IL-2 binding, but not IL-2-driven growth) was completely ineffectual. Simultaneous targeting of two IL-2R epitopes increased the therapeutic index synergistically (ART-18 [R1] + ART-65 [R2].sbd.60% permanent graft acceptance), additively (ART-75 [R1] + ART-35 [R3].sbd.graft survival ca. 18 days), or did not improve further graft survival at all (ART-18 [R1] + OX-39 [R4].sbd.graft survival ca. 18 days). Thus, the cellular targeting patterns and isotype of mAbs are crucial: (1) targeting at functionally distinct epitopes controls rejection most effectively; (2) IgG1 and IgG2b mAbs are more influential in vivo than IgG2a, data supported by the studies employing the family of ART-18 isotype switch variants. Treatment with anti-IL-2R mAb did not depress Ts activity as tested both in vitro and in vivo. Sparing of putative Ts by mAb is also shown by thymectomy of graft recipients before or during ART-18 therapy, which shortened graft survival to 13-15 days; thymectomy after ART-18 therapy did not influence graft survival. However, infusion of IFN-.gamma. recreated classic acute rejection within 10 days in otherwise longstanding cardiac allografts in ART-18 treated hosts. Upregulation of MHC class II antigen and IL-2R expression seems to be primarily responsible for this striking biological effect of IFN-.gamma. in vivo. These experiments stress the positive and negative interactions between anti-IL-2R mAbs themselves and feedbacks with the host immune system.This publication has 17 references indexed in Scilit:
- PREVENTION OF REJECTION OF KIDNEY TRANSPLANTS BY MONOCLONAL ANTIBODY DIRECTED AGAINST INTERLEUKIN 2The Lancet, 1987
- Inhibitory effects of anti-interleukin 2 receptor and anti-L3T4 antibodies on delayed type hypersensitivity: the role of complement and epitope.The Journal of Immunology, 1987
- Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors.Proceedings of the National Academy of Sciences, 1987
- Novel Interleukin-2 Receptor Subunit Detected by Cross-Linking Under High-Affinity ConditionsScience, 1986
- Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.Proceedings of the National Academy of Sciences, 1986
- Cloning and expression of the chromosomal immune interferon gene of the rat.The EMBO Journal, 1985
- Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies.The Journal of Experimental Medicine, 1985
- A rat monoclonal antibody that binds specifically to mouse T lymphoblasts and inhibits IL 2 receptor functions: a putative anti-IL 2 receptor antibody.The Journal of Immunology, 1984
- Identification and initial characterization of a rat monoclonal antibody reactive with the murine interleukin 2 receptor-ligand complex.Proceedings of the National Academy of Sciences, 1983
- A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.The Journal of Immunology, 1981